SFM
HAE icon

Soros Fund Management’s Haemonetics HAE Stock Holding History

Soros Fund Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-33,200
Closed -$3.69M – 267
2021
Q1 		$3.69M Buy
+33,200
New +$4.11M 0.07% 146

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
LCOV
London Company of Virginia Richmond, Virginia $16.2B AUM 17.5% 1-Year Est. Return
LCP
LGT Capital Partners Pfaeffikon, Switzerland $1.88B AUM 20.37% 1-Year Est. Return

Soros Fund Management's HAE Position: Q2 2021 in Review

Soros Fund Management sold out of Haemonetics (HAE) in Q2 2021, closing a stake of 33,200 shares — an estimated $3.69M sold.

Soros Fund Management first reported a position in HAE in Q1 2021 and held it in 1 quarter. The position peaked at $3.69M in Q1 2021. 258 funds tracked by Wall St. Rank hold HAE as of Q2 2021.

  • Soros Fund Management reported no remaining Haemonetics position as of Q2 2021 after selling out during the quarter.
  • Soros Fund Management sold 33,200 Haemonetics shares in Q2 2021, an estimated $3.69M.
  • Soros Fund Management first reported a position in Haemonetics in Q1 2021 and held it in 1 quarter.
  • Soros Fund Management's Haemonetics position peaked at $3.69M in Q1 2021.
  • 258 funds tracked by Wall St. Rank held Haemonetics as of Q2 2021.

Based on Soros Fund Management's 13F filing for Q2 2021, filed 13 Aug 2021.